Lynk Pharmaceuticals has received the green light from the U.S. Food and Drug Administration (FDA) to begin clinical trials of its investigational oral therapy LNK01006, which is being developed for multiple sclerosis (MS) and other neuroinflammatory diseases. “We look forward to advancing this promising molecule into human clinical trials and bringing new therapeutic options to […]
The post FDA clears clinical trials for Lynk’s oral MS therapy appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com